Market Overview

UPDATE: Jefferies & Company Initiates Coverage on Antares Pharma with Buy Rating, $5 PT

Share:
Related ATRS
Benzinga's Top Initiations
Piper Jaffray Initiates Antares Pharma With Overweight

In a report published Wednesday, Jefferies & Company initiated coverage on Antares Pharma (NASDAQ: ATRS) with a Buy rating and $5.00 price target.

Jefferies noted, “We are initiating on ATRS with a Buy and a 12-month $5 price target. ATRS is a needle auto-injector innovator transitioning from a device technology partner to an integrated commercial-stage drug company. The primary driver is a self-injected once-weekly form of methotrexate for RA (NDA filed 12/17/12) with better safety and efficacy potential. In the meantime, several already-partnered drugs should fund pre-launch preparations in '13.”

Antares Pharma closed on Tuesday at $3.82.

Latest Ratings for ATRS

DateFirmActionFromTo
May 2015JefferiesInitiates Coverage onBuy
May 2015Piper JaffrayInitiates Coverage onOverweight
Oct 2014JMP SecuritiesInitiates Coverage onOutperform

View More Analyst Ratings for ATRS
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Initiation Analyst Ratings

 

Related Articles (ATRS)

Around the Web, We're Loving...

Get Benzinga's Newsletters